| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| Other Sizes |
| Targets |
Carboxypeptidase N (CPN)
|
|---|---|
| ln Vitro |
Mergetpa functions as a carboxypeptidase inhibitor. Its mechanism is to impede the conversion of kinins and B2 receptor antagonists into metabolites devoid of the C-terminal arginine. By blocking this activity, it can potentiate the effects of kinins and inhibit the inactivation of anaphylatoxins in plasma.
|
| ln Vivo |
Currently, no specific in vivo data is available for this compound. General in vivo information for similar carboxypeptidase inhibitors may include their ability to potentiate bradykinin-induced hypotension and modulate inflammatory responses in animal models.
|
| Enzyme Assay |
A typical carboxypeptidase N inhibition assay protocol involves incubating the compound with purified CPN enzyme and a synthetic substrate like hippuryl-L-arginine in a Tris-HCl buffer at 37degC. The reaction is stopped by heating, and the released arginine is measured using a colorimetric assay or by HPLC.
|
| Cell Assay |
General in vitro cellular protocols for studying carboxypeptidase inhibitors often use plasma or serum. The compound is spiked into human plasma, and the degradation of a synthetic bradykinin peptide is monitored over time by LC-MS/MS to assess the inhibitor's ability to prevent kinin breakdown.
|
| Animal Protocol |
General in vivo procedures for studying carboxypeptidase N inhibitors involve administering the compound intravenously to anesthetized rats. Blood pressure is monitored via a carotid artery catheter. The compound is given as a bolus, followed by or co-administered with bradykinin to measure the potentiation of the hypotensive effect.
|
| ADME/Pharmacokinetics |
Mergetpa has a molecular weight of 237.34. As a small molecule containing a thiol group, it may be subject to rapid oxidation and protein binding in vivo. General PK properties for similar thiol compounds often include a short half-life, moderate plasma stability, and rapid renal clearance.
|
| Toxicity/Toxicokinetics |
The compound contains a thiol group and may be toxic, classified as an air-sensitive and hygroscopic substance. Handling requires appropriate safety precautions, including use of a fume hood and personal protective equipment. No specific LD50 or detailed safety data is available for research use.
|
| References | |
| Additional Infomation |
3-((2-((Aminoiminomethyl)amino)ethyl)thio)-2-(mercaptomethyl)propanoic acid is the (+-)-isomer; see the first source for its structure.
Mergetpa is a research tool used to study the role of carboxypeptidase N in the kinin-kallikrein system and complement system. Carboxypeptidase N is a major inactivator of bradykinin and anaphylatoxins (C3a, C5a). Mergetpa has potential applications in studying thrombolysis. It is not an approved drug. |
| Molecular Formula |
C7H15N3O2S2
|
|---|---|
| Molecular Weight |
237.34
|
| Exact Mass |
237.061
|
| CAS # |
77102-28-4
|
| PubChem CID |
123726
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.024
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
14
|
| Complexity |
207
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CSCC(CS)C(=O)O)N=C(N)N
|
| InChi Key |
AKPKWZRKZOAAAZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H15N3O2S2/c8-7(9)10-1-2-14-4-5(3-13)6(11)12/h5,13H,1-4H2,(H,11,12)(H4,8,9,10)
|
| Chemical Name |
2-[2-(diaminomethylideneamino)ethylsulfanylmethyl]-3-sulfanylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 15 mg/mL (63.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2134 mL | 21.0668 mL | 42.1336 mL | |
| 5 mM | 0.8427 mL | 4.2134 mL | 8.4267 mL | |
| 10 mM | 0.4213 mL | 2.1067 mL | 4.2134 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
